Table 2.
The role of the C/EBPβ isoform in inflammation.
| C/EBPβ isoforms | Reference | ||||
|---|---|---|---|---|---|
| Structural Features | LAP1 | LAP2 | LIP | ||
| Full-length N-terminal transactivation domain (TAD) | Lacking 21 amino acids at the N-terminal TAD and partially regulatory | Completely lacking the N-terminal TAD and Lacking most of the negative regulatory domain |
(30) | ||
| Primary Functions | Increase transcriptional activity | Increase transcriptional activity | Inhibit transcriptional activity | (31) | |
| Diseases Mechanisms | Lupus nephritis | C/EBPβ-LAP upregulates AIM2 inflammasome activity by promoting the transcriptional expression of AIM2 and CASPASE1 through direct promoter binding | C/EBPβ-LIP suppresses IRAG expression at the transcriptional level, enhancing Ca²+ release and subsequent AIM2 inflammasome activation | (71) | |
| Chronic inflammation | LAP isoforms promote inflammation by activating the transcription of pro-inflammatory genes, including IL-6 and TNFα | LIP reduces inflammation by blocking LAP | (77) | ||